Editorial: Community series in the role of CD1- and MR1-restricted T cells in immunity and disease: volume III
induced pluripotent stem cell (iPSC)-derived iNKT cells, and iPSC-CAR-iNKT cells, which may accelerate the development of safe and effective iNKT cell therapies. Moreover, the review discusses iNKT cell-based combination therapies with radiotherapy, monoclonal antibodies, immune modulators, and others.The review by Laub, Rodrigues de Almeida, and Huang covers tumor immunotherapy by mainly focusing on MR1-restricted T cells, as compared with iNKT cells and gd T cells. The advantage of utilizing unconventional T cells for immunotherapy is based on their public TCRs that recognize non-peptidic antigens presented by non-polymorphic or minimally polymorphic MHC class I-like molecules. While MR1 is ubiquitously expressed, it is largely confined to intracellular compartments in the absence of specific ligands (11). Hence, target cells for MR1-restricted T cells need to produce endogenous activating ligands. MR1-restricted T cells can be activated or inhibited by a variety of self-, tumor-, or microbial-derived products and drug-like molecules such as vitamin B-related metabolites, nucleosides, nucleoside adducts, and their synthetic analogues. The authors discuss the properties of human MR1-restricted T cell clones that recognize specific MR1 allomorphs on a wide range of tumor cells but not healthy cells, suggesting a new avenue for MR1-based immunotherapies. Finally, they discuss the current status and future perspectives of clinical trials for cancer immunotherapies conducted with these unconventional T cell subsets. -4-Seminal studies in the field reported the capacity of members of the CD1 family to present mycobacterial lipids to CD1-restricted T lymphocytes (12). These studies spurred the discovery of a burgeoning family of unconventional T cells that recognize non-peptidic antigens presented by MHC class Ib proteins. The review by Milton and Mansour describes the antigen-presenting functions of each member of the CD1 family, and further discusses the responses of subsets of CD1-restricted ab and gd T cells to mycobacterial infections and autoantigens. They also highlight earlier findings that different mammalian species express different numbers of CD1 genes, which has important implications for selecting appropriate animal species to model disease (13). Importantly, they remind readers that toll-like receptor signaling can modulate CD1-mediated T cell responses, including those directed against mycobacterial infections. Prospects for incorporating this knowledge into new vaccine candidates are discussed.MAIT cells can be activated by cytokines such as IL-12 and IL-18, even in the absence of TCR signals (14), and the effector functions of these cells can be modulated by type I interferons, IL-7, IL-15, and IL-23 (15). The review by Camard, Bianchi, and Rogge discusses MAIT cells that are thymically pre-programmed to produce type 1 or 3 cytokines (i.e., MAIT1 or MAIT17 cells, respectively), the peripheral tissues they occupy, and their functions in tissue repair and cytocidal activity, which may be influenced by the specific cytokine milieu in which they reside, even under physiological conditions. The review then considers the contributions of these cells to bacterial and viral infections that are either dependent or independent of TCR engagement. Finally, they discuss the impact of human inborn errors of immunity, due to defects in genes related to MR1, RORgt and related cytokines and cytokine receptors, on MAIT cell functions and their contributions to health and disease.Finally, the original research article by Zhang and Liu presents a bibliometric analysis of the iNKT cell literature in the Web of Science Core Collection (WSCC) database. Over three thousand studies were pared down by removing meeting abstracts, editorials, corrections, retracted papers, etc., to reach a final list of 2,579 studies that were analyzed for temporal distribution of publications, country -5-of origin, institutional networks, journals, and specific scientists associated with top-ranked research.Such analysis can provide insight into the progression of a research field through specific milestones and collaborations, in efforts to make informed decisions about future research directions.In summary, the articles contained in Volume III of this Community Series provide a snapshot of the biology and potential medical applications of CD1-and MR1-restricted T cells. We hope that these articles will spawn new studies with the ultimate goal to bring unconventional T cells from the lab to patient care.
Authors
- Kazuya Iwabuchi
- Luc Van Kaer
Institutions
- Vanderbilt University (US)
- Kitasato University (JP)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-26
- DOI
- https://doi.org/10.3389/fimmu.2026.1783936
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Heart Association
- Ministry of Education, Culture, Sports, Science and Technology
- National Institutes of Health